An observational study in Heart Disease, sponsored by Taewoong Medical Co., Ltd.. Not yet recruiting at 9 sites in 6 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Heart Diseases with a site in Korea, Republic of — 8 open to participants now, 10 under way, 2 of them phase 3. Heart Diseases · Korea, Republic of.
Among the 31 studies in Heart Diseases with a site in Korea, Republic of, this one is the only one that started in 2026, is one of 8 observational ones, and was the 31st registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →8 of the 31 studies in Heart Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, Argentina, Australia and 35 more countries
Ages 50+
Eidos Therapeutics, a BridgeBio company · Sites in Korea, Republic of, United States, Argentina and 21 more countries
Ages 18–75
Weill Medical College of Cornell University · Sites in Korea, Republic of, United States, Australia and 23 more countries
Ages 18+ · Women only
Kangbuk Samsung Hospital · Sites in Korea, Republic of
Ages 18+
Jung-min Ahn · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 350 across 592 observational studies indexed under Heart Diseases.
Median enrollment 632 across the 23 interventional studies, 1,100 across the 8 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taewoong Medical Co., Ltd., one of the names counted as Olympus Corporation. Under that name alone:
Taewoong Medical Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Olympus Corporation has 2 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Diseases with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT05846893B. Braun Medical Industries Sdn. Bhd.Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Heart Diseases with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the long-term follow-up clinical outcomes, effectiveness, and safety data of the PULSTA Transcatheter Pulmonary Valve (TPV) implantation in a real-world situation
The PULSTA TPV is a self-expandable valve with flared-ends to adapt to the larger native right ventricular outflow tract (RVOT) and is using a relatively low profile delivery catheter from knitted nitinol wire backbone and trileaflets made from treated porcine pericardial tissue, and a delivery system, which provides access to the right ventricular outflow tract through blood vessels. This registry will collect real-world clinical data on patients undergoing PULSTA TPV implantation at discharge and at 1 month, 6 months, and annually for up to 5 years after implantation.
Patients with right ventricular outflow tract (RVOT) dysfunction who are considered eligible for percutaneous pulmonary valve implantation (PPVI) with the PULSTA TPV according to the approved indication and routine clinical practice at participating centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-arm cohort consisting of all eligible patients undergoing percutaneous pulmonary valve implantation(PPVI) with the PULSTA TPV as part of routine clinical care
Procedural / device-related serious adverse events at 12 months
Time frame: 12 months
Hemodynamic functional improvement at 12 months
Hemodynamic functional improvement is defined as the achievement of both of the following criteria: * Mild or less pulmonary regurgitation measured by echocardiography AND * Mean Right Ventricular Outflow Tract(RVOT) pressure gradient measured by echocardiography ≤35mmHg
Time frame: 12 months
Procedural success
Procedural success is defined as the Transcatheter Pulmonary Valve(TPV) implant in on the desired site, Right ventricle-Pulmonary artery (RV-PA) peak systolic pressure gradient \<35mmHg by cardiac catheterization, less mild pulmonary regurgitation by angiography, and freedom from explantation of the TPV at 24 hours following implantation.
Time frame: 24 hours
Hemodynamic function at all follow-up visits
Hemodynamic function will be assessed including: * Peak RVOT pressure gradient (by echocardiography) * Mean RVOT pressure gradient (by echocardiography)
Time frame: 5 years
Severity of pulmonary regurgitation (by echocardiography)
Severity of pulmonary regurgitation will be measured by Doppler echocardiography and classified into none, trace/trivial, mild, moderate, and severe.
Time frame: 5 years
NYHA functional classification
Clinical outcome will be assessed as per the New York Heart Association (NYHA) functional classification at all follow-up visits and will be compared to baseline values.
Time frame: 5 years
Freedom from death
Frequency of all cause / cardiac / non-cardiac / procedural-related / device-related deaths during the 5-year follow-up period
Time frame: 5 years
Freedom from re-operation
Reoperation is defined as open surgery that alters or adjusts, or replaces a previously implanted PULSTA
Time frame: 5 years
Freedom from catheter re-intervention
Any interventional catheter procedure (e.g. balloon angioplasty) that alters or adjusts, or replaces a previously implanted PULSTA TPV
Time frame: 5 years
Freedom from TPV dysfunction
Moderate or greater pulmonary regurgitation, clinically significant RVOT obstruction (mean RVOT gradient \>35 mmHg), or any valve-related event requiring re-intervention or re-operation
Time frame: 5 years
Incidence of procedural- and device-related adverse events
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jul 2028, 21 months later.
Of 54 industry-sponsored observational studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 65. This study's planned 21 months is below that.
Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.